Diabetic patients show a high prevalence of hypertension and angina, but are also prone to hypoglycemia (defined as a blood glucose of less than 3 mmol/l, although symptoms of hypoglycaemia may occur with higher levels wherever there has been a rapid fall in the blood sugar). The symptoms may mimic those of cerebral anoxia, since cerebral metabolism is dependent upon an adequate supply of blood glucose, and the clinical picture may range from the patient merely feeling faint, through to convulsions and deep coma. The adrenergic signs of tachycardia, sweating and tremor, occur whenever there is a rapid fall in blood sugar, and these are useful because they warn the diabetic or his colleagues of the pending attack. The most common cause of hypoglycemia is drug-induced, and beta-adrenergic blockers are only one of many classes of drug which can be responsible. Many reports have shown that beta-blocking drugs may (1) potentiate the action of insulin and oral hypoglycwmics, (2) interfere with the recovery mechanisms of the body from hypoglycemia, and (3) block the clinical signs of sweating, tachycardia and tremor by which we recognize hypoglycmemia. Most of the clinical experience with beta blockers has been restricted to propranolol, which is a nonselective beta blocker. Beta, receptors are predominantly distributed in the cardiovascular system, and beta2 receptors tend to occur in the periphery: veins, bronchi, skeletal muscles, pancreas and liver. It is beta2 blockade which has been thought to be responsible for the hypoglycemic effects of nonselective blockers.
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Trial Design
With the introduction of the new cardioselective drugs such as atenolol, it was suggested that they might be free of hypoglycemic side effects and thus preferable for use in patients such as diabetics who are prone to hypoglyc=mia. It was to test this hypothesis that Dr Barnett of Leeds and I performed a relatively simple study to look at the effects of atenolol and propranolol on insulininduced hypoglycemia. The study was performed in 8 healthy subjects, one female and 7 males, aged 22 to 29 years. They underwent three episodes of insulin-induced hypoglycaemia, at approximately seven-day intervals and during the period of the study they took their normal diet, avoided alcoholic abuse and avoided excessive, prolonged exercise. For 48 hours before each episode of hypoglycemia they were predosed either with atenolol 50 mg twice daily, propranolol 80 mg twice daily or placebo twice daily. These were administered in a double-blind manner using identical capsules. The patients were fasted overnight and on attending at hospital were made comfortable, semi-recumbent on a couch, and indwelling cannulae were inserted. The patients were then allowed to rest to get used to this needle, and after a 15 minutes' equilibration period, pulse rates and fasting blood samples were taken. They then received an intravenous bolus of 0.1 unit/kg insulin, and further blood samples were taken at 30 minute intervals for two hours. During the study they were asked to note their autonomic disturbances, particularly sweating, which was assessed on an arbitrary scale of 0 (normal) to 3 (profuse).
Results
On the morning of the test, before insulin was administered, the pulse rates with atenolol and propranolol were significantly and similarly depressed by about 12 beats/minute, which indicated that the tablets had been taken, and indeed throughout the period of hypoglycemia, E] Placebo 9 Atenolol 0 Propranolol pulse rate remained depressed, indicating effective beta blockade (Fig 1) . The pulse rates for atenolol and propranolol were similar throughout apart from the 30 minute value, which corresponded to the period of maximum hypoglycemia when there was a small but significant increase in pulse rate with atenolol equal to about 6 beats/minute. Sweating was difficult to assay but there was no ] Placebo a Atenolol , significant difference in the intensity of sweating between the three treatments at 30 minutes, which corresponded to the maximum hypoglyczemic period. In the recovery phase the period of sweating was prolonged with propranolol while with atenolol and placebo it settled fairly promptly (Fig 2) .
In the fasting state there were no differences in the blood sugar levels. At 30 minutes following insulin there was quite a profound hypoglycemic fall of some 68 % on the fasting blood sugar level but it was not possible to show any potentiation of the effect of insulin with either drug (Fig 3) . In the recovery phase placebo and atenolol came up together, and at the two-hour period there was a remaining blood glucose deficit of 8 % with placebo and 12% with atenolol. However, the propranolol phase was significantly depressed, and at two hours there was still a 31 % deficit in the blood sugar level. This correlates with the 4.0-^3 sweating scores and those subjects on propranolol remained hypoglycamic with continuing autonomic disturbances. This relatively simple study showed that atenolol, in normal subjects, under the circumstances of our trial, did not delay the recovery from hypoglyctemia.
Discussion
Since this work was published there have been one or two other publications on this topic. Newman (1976) used a very similar study protocol in 11 healthy male subjects who were predosed for 48 hours before each test with propranolol (40 mg twice a day), metoprolol (50 mg twice a day), acebutolol (100 mg twice a day) or placebo, in a single-blind manner. The pulse rates on beta blockers remained depressed throughout the pefiod of hypoglycemia, indicating effective beta blockade. At 30 minutes there was a significant but small potentiation of the effect of insulin with all three beta blockers (Fig 4) . With propranolol and metoprolol there was a depression of the blood glucose recovery as compared with the placebo. The acebutolol curve was not significantly different from placebo. The mean deficits at two (Newman 1976) hours were placebo 8%, acebutolol 15%, metoprolol 20 % and propranolol 25 %. Linton et al. (1976) looked at the effects of i.v. propranolol (0.15 mg/kg), metoprolol (0.3 mg/kg) and acebutolol (1.0 mg/kg) on respiratory function during exercise, and also assayed blood sugars. The subjects attended hospital having taken a light breakfast. They were then exercised sub-maximally for three-minute intervals on a bicycle ergometer, before and at half-hourly intervals following an intravenous bolus of one of the beta blockers. During the morning the blood sugars fell gradually, until they had lunch after 4 hours (Fig 5) . One way of assessing the potentiation of hypoglycemia is to consider the area bounded by the curve below a horizontal line drawn through the initial value. This percentage expression of potentiation shows that metoprolol potentiated hypoglycaemia during the study by 54 %, acebutolol by 95 % and propranolol by 107% over and above placebo. This is a chronic study and the results for acebutolol and metoprolol are interesting in that they are the reverse of Dr Newman's. From these studies there is some evidence to suggest that the cardioselective betablocking drugs may be free of hypoglycremic effects, and there seems to be some difference between the different drugs.
The maintenance of blood glucose involves a complicated interplay of many physiological aspects of body biochemistry. On the one hand there is the ingestion and assimilation of carbo- hydrate by the gut, plus hepatic glycogenolysis and also gluconeogenesis. This is balanced by tissue uptake and utilization. Beta blockers could be involved at any part of the equation. Acute hypoglycemia represents a very severe insult to the body, and causes the release of several hormones to restore the balance to normalcortisol, catecholamines, hormones and glucagon which act to bring the blood sugar up to a normal level. Of these the most important are probably the catecholamines. Beta2 receptors are thought to be peripherally distributed and involved in the recovery mechanisms from hypoglycemia. These hiclude hepatic and skeletal muscle glycogenolysis. Although the latter source cannot contribute directly to the blood glucose pool, lactate feedback from muscles to the liver enables increased gluconeogenesis to occur. Hepatic glycogenolysis plus lactate feedback for gluconeogenesis are probably the most important mechanisms in the restoration of blood sugar levels.
The effects of adrenaline in the liver have been studied extensively and most workers have concluded that the adrenergic receptor of the liver cannot really be classified as alpha or beta. Present opinion is swinging around to the concept that, if anything, the liver receptors are nearer a beta receptor and probably a beta2 receptor. Infusions of salbutamol, a beta2agonist, will increase blood glucose levels in the intact animal. Catecholamines are probably acting at a membrane level, and are stimulating adenyl cyclase which increases cellular AMP, and by this mechanism the processes of hepatic glycogenolysis and gluconeogenesis are swung into play. This is a very complex biochemical interplay and such factors as steroid hormones, calcium and ionic shifts all play some part in the modification of cyclic AMP activity and perhaps cardioselectivity is not the only answer.
In a recent comparative study (Davidson et al. 1976 ) it was shown that the ancillary pharmacological properties do not appear to influence the antihypertensive activity of various beta blockers. However, it is possible that both ISA and/or MSA play some part in their biochemical metabolic effects. There has been some animal work to show that MSA may be important in its effects on hepatic glycogenolysis (Pogatsa 1975) . Rat liver perfusion studies showed that the suggested beta2 stimulation of hepatic glycogenolysis by catecholamines was blocked with nonselective drugs such as propranolol and pindolol. The absence of glucose in perfusing fluid acts as a stimulus to hepatic glycogenolysis. Drugs such as propranolol, with MSA, block this response, but drugs such as pindolol, which lack MSA but are not cardioselective, do not block it.
Summary
The hypoglycimic action of beta blockers s5 to be related to selectivity, and memb stabilizing activity. It is possible to categoriz beta blockers relative to their ability to ( blood glucose recovery. The cardiosele blockers, such as atenolol and practolol, been shown not to delay blood glucose reco' However, pindolol has been shown in 1 circumstances not to delay blood glu recovery, although it is not cardioselective. information on metoprolol and acebutolb disputed, and needs to be more clearly def Propranolol, even in doses of 80 mg/day, I hypoglycimic effect.
The findings presented suggest that cai selective beta blockers may be free of troi some hypoglycimic side effects and as such in future be preferable in use with dia patients. These findings are open to criti( being derived from studies in healthy individ and as such are not strictly applicable to diab4 To meet this criticism Dr Barnett and I ai present conducting a similar study in dia patients, and it is felt that if these findings ca confirmed in diabetics then a safer therap approach to hypertension in such patients have been made available.
